GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (MEX:OPK) » Definitions » Cyclically Adjusted PS Ratio

OPKO Health (MEX:OPK) Cyclically Adjusted PS Ratio : 0.61 (As of May. 22, 2025)


View and export this data going back to 2011. Start your Free Trial

What is OPKO Health Cyclically Adjusted PS Ratio?

As of today (2025-05-22), OPKO Health's current share price is MXN25.12. OPKO Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN41.25. OPKO Health's Cyclically Adjusted PS Ratio for today is 0.61.

The historical rank and industry rank for OPKO Health's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:OPK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.48   Med: 2.97   Max: 117.87
Current: 0.64

During the past years, OPKO Health's highest Cyclically Adjusted PS Ratio was 117.87. The lowest was 0.48. And the median was 2.97.

MEX:OPK's Cyclically Adjusted PS Ratio is ranked better than
83.33% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06 vs MEX:OPK: 0.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

OPKO Health's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN4.568. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN41.25 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


OPKO Health Cyclically Adjusted PS Ratio Historical Data

The historical data trend for OPKO Health's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health Cyclically Adjusted PS Ratio Chart

OPKO Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 3.21 0.73 0.81 0.74

OPKO Health Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.64 0.76 0.74 0.82

Competitive Comparison of OPKO Health's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, OPKO Health's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where OPKO Health's Cyclically Adjusted PS Ratio falls into.


;
;

OPKO Health Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

OPKO Health's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=25.12/41.25
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OPKO Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, OPKO Health's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=4.568/134.9266*134.9266
=4.568

Current CPI (Mar. 2025) = 134.9266.

OPKO Health Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.440 100.684 1.930
201509 4.689 100.392 6.302
201512 8.755 99.792 11.837
201603 9.179 100.470 12.327
201606 11.856 101.688 15.731
201609 10.435 101.861 13.822
201612 6.124 101.863 8.112
201703 8.982 102.862 11.782
201706 9.375 103.349 12.239
201709 7.982 104.136 10.342
201712 5.651 104.011 7.331
201803 8.278 105.290 10.608
201806 9.260 106.317 11.752
201809 8.347 106.507 10.574
201812 7.592 105.998 9.664
201903 7.359 107.251 9.258
201906 7.416 108.070 9.259
201909 7.703 108.329 9.594
201912 6.794 108.420 8.455
202003 7.741 108.902 9.591
202006 10.853 108.767 13.463
202009 14.759 109.815 18.134
202012 15.357 109.897 18.855
202103 17.389 111.754 20.995
202106 13.611 114.631 16.021
202109 12.170 115.734 14.188
202112 12.624 117.630 14.480
202203 9.927 121.301 11.042
202206 8.749 125.017 9.443
202209 4.818 125.227 5.191
202212 4.806 125.222 5.178
202303 5.698 127.348 6.037
202306 6.053 128.729 6.344
202309 4.139 129.860 4.301
202312 4.106 129.419 4.281
202403 4.078 131.776 4.175
202406 4.787 132.554 4.873
202409 3.424 133.029 3.473
202412 5.657 133.157 5.732
202503 4.568 134.927 4.568

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OPKO Health  (MEX:OPK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


OPKO Health Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of OPKO Health's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OPKO Health Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.